Precigen Reports Full Year 2025 Financial Results and Business Updates [Yahoo! Finance]
Precigen, Inc. (PGEN)
Last precigen, inc. earnings: 3/2 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
imadenovec-drba), the first-and-only FDA-approved treatment for adults with RRP, in August 2025 PAPZIMEOS generated $3.4 million in net product revenue in the fourth quarter of 2025, reflecting the first partial quarter of US commercial sales as payer policies came into effect; the US launch continues to build strong momentum, with a significant increase in demand in the first quarter of 2026 The Centers for Medicare and Medicaid Services has assigned a permanent J-code, J3404, to PAPZIMEOS, effective April 1, 2026, streamlining the claims process and facilitating broader patient access Marketing Authorization Application for PAPZIMEOS for the treatment of adults with RRP validated by the European Medicines Agency and is under review Open-label redosing study initiated to evaluate retreatment efficacy of zopapogene imadenovec in adults with RRP Expert consensus paper sponsored and published by the Recurrent Respiratory Papillomatosis Foundation and authored by 16 leading phy
Show less
Read more
Impact Snapshot
Event Time:
PGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PGEN alerts
High impacting Precigen, Inc. news events
Weekly update
A roundup of the hottest topics
PGEN
News
- Discover Precigen And 2 Other Insider-Favored Growth Stocks [Yahoo! Finance]Yahoo! Finance
- Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge? [Yahoo! Finance]Yahoo! Finance
- Precigen (PGEN) had its price target raised by Citizens Jmp from $8.00 to $9.00. They now have a "market outperform" rating on the stock.MarketBeat
- Precigen gains after 2025 results on Papzimeos outlook [Seeking Alpha]Seeking Alpha
- Precigen (PGEN) had its price target raised by HC Wainwright from $9.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
PGEN
Earnings
- 3/25/26 - Miss
PGEN
Sec Filings
- 3/25/26 - Form 10-K
- 3/25/26 - Form 8-K
- 3/20/26 - Form 4
- PGEN's page on the SEC website